Loading...
XWAR
SPH
Market cap425mUSD
Jul 22, Last price  
12.75PLN
Name

Sopharma AD

Chart & Performance

D1W1MN
XWAR:SPH chart
P/E
9.35
P/S
0.34
EPS
0.63
Div Yield, %
1.54%
Shrs. gr., 5y
5.53%
Rev. gr., 5y
10.69%
Revenues
2.13b
+12.77%
644,731,000688,579,000762,689,000840,517,000874,984,000877,085,0001,017,105,0001,179,143,0001,281,587,0001,438,826,0001,603,310,0001,662,992,0001,887,947,0002,129,097,000
Net income
76m
-19.85%
38,404,00035,196,00029,248,00020,178,00021,314,00050,638,00039,998,00028,343,00086,994,00029,805,00089,496,00071,121,00095,207,00076,310,000
CFO
77m
+70.38%
38,404,00035,196,00029,248,00020,178,00021,314,00050,638,00039,998,00028,343,000-128,443,999-179,411,000-75,963,000124,622,00045,033,00076,728,000
Dividend
Jul 11, 20240.19638 PLN/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Sopharma AD researches and develops, produces, and trades in medicinal substances, finished drug forms, veterinary vaccines, infusion solutions, and plastic medical disposable products for human and veterinary medicine, and food supplements in Bulgaria and internationally. It offers products in various therapeutic areas, such as cardiology, gastroenterology, pain management, cough and cold, immunology and dermatology, respiratory and asthma, neurology and psychiatry, urology, and gynecology. The company's products comprise Carsil to treat gastroenterological disorders; Tempalgin, an analgesic; Tabex, a plant-based drug used for smoking secession; Tribestan, a plant-based drug used for stimulation of functions of the sexual system; Broncholytin, which is used to suppress cough; Analgin, a generic analgesic; Nivalin, a plant-based product used for diseases of the peripheral nervous system; and Methylprednisolon, a general medicine for cases of severe allergies and life-threatening conditions. It also trades in food supplements; provides secondary packaging services for pharmaceutical products and real estate leases; trades, transports, and packages radioactive materials and nuclear equipment for medicinal use, household electronics, and electrical equipment; and purchases, collects, grows, produces, and trades in herbs and medicinal plants. In addition, the company engages in the retail trade of medicinal products and medical equipment; production of non-medicinal, and other products; and franchising, know-how, and rental of properties, as well as in trading, consulting, and other activities. Further, it offers market and public opinion research services; and engages in non-pharma activities, such as veterinary vaccines, infusion solutions. Sopharma AD was founded in 1933 and is headquartered in Sofia, Bulgaria.
IPO date
Jan 20, 1998
Employees
4,770
Domiciled in
BG
Incorporated in
BG

Valuation

Title
BGN in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT